On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial.
James Paul Dean
No relevant relationships to disclose
Robert B. Montgomery
No relevant relationships to disclose
Junxiang Wan
No relevant relationships to disclose
Pinchas Cohen
No relevant relationships to disclose
Kathleen Haugk
No relevant relationships to disclose
John M Corman
No relevant relationships to disclose
William J Ellis
No relevant relationships to disclose
Bruce L Dalkin
No relevant relationships to disclose
Dale L. Ludwig
No relevant relationships to disclose
Stephen R Plymate
No relevant relationships to disclose